Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.58 |
| ▸ | RXRB | P28702 | 4/20 | 0.58 |
| ▸ | RXRG | P48443 | 3/20 | 0.58 |
| ▸ | RARB | P10826 | 11/20 | 0.53 |
| ▸ | RARG | P13631 | 11/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | RARA | P10276 | 9/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839209 | 0.84 | RXRA (0.56) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL10646332 | 0.83 | RARB (0.66) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL10646335 | 0.83 | RARB (0.66) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL13712347 | 0.81 | SMN1; SMN2 (0.45) | RXRARXRBRXRGCYP3A4NR1H2 | |
| SCHEMBL9446452 | 0.79 | KMT2A (0.72) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL8839069 | 0.79 | RXRA (0.50) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8462086 | 0.79 | RARG (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL10729678 | 0.79 | RARG (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8462084 | 0.79 | RARG (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9523050 | 0.79 | RXRA (0.50) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | RXRA 1135/4885RXRB 1301/4885RXRG 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.